Unicycive Therapeutics, Inc.
UNCY
$5.86
-$0.14-2.33%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -46.73% | -165.42% | 102.72% | -176.03% | 5.47% |
| Total Depreciation and Amortization | 20.33% | 222.12% | -52.46% | 63.41% | 55.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 70.67% | 101.22% | -163.14% | 509.51% | -146.04% |
| Change in Net Operating Assets | 105.74% | -2,237.04% | -196.30% | 51.83% | -1,481.27% |
| Cash from Operations | 35.56% | -33.25% | -37.90% | -47.51% | -109.23% |
| Capital Expenditure | 91.67% | 70.00% | -166.67% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 91.67% | 70.00% | -166.67% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -419.11% | -221.83% | 94.34% | -55.12% | -207.84% |
| Cash from Financing | 16,871.97% | 1,454.38% | -94.43% | 278.05% | -207.84% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 315.92% | 135.78% | -116.25% | -33.61% | -110.89% |